Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.54 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.54 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.50 |
| ▸ | KIT | P10721 | 2/20 | 0.50 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.50 |
| ▸ | RAF1 | P04049 | 1/20 | 0.50 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.50 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 7/20 | 0.45 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.44 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.44 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.42 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10069533 | 0.85 | MKNK1 (0.43) | MKNK1MKNK2MAPK11MAPK14KIT | |
| SCHEMBL10070508 | 0.85 | NR1H2 (0.45) | AOC3TLR9TLR8TLR7USP30 | |
| SCHEMBL10070058 | 0.84 | USP30 (0.56) | AOC3TLR9TLR8TLR7USP30 | |
| SCHEMBL2972353 | 0.83 | MKNK1 (0.52) | MKNK1MKNK2MAPK11MAPK14MAPK13 | |
| SCHEMBL10070112 | 0.83 | CPT1A (0.45) | MKNK1MKNK2KITTLR9TLR8 | |
| SCHEMBL12231269 | 0.77 | KIT (0.52) | MAPK11MAPK14KITAOC3USP30 | |
| SCHEMBL10070509 | 0.77 | CPT2 (0.45) | MKNK1MKNK2AOC3USP30 | |
| SCHEMBL4543850 | 0.75 | SSTR3 (0.39) | MKNK1MKNK2MAPK11MAPK14KIT | |
| SCHEMBL10070543 | 0.74 | GABRA1 (0.45) | TLR9TLR8TLR7USP30 | |
| SCHEMBL31628181 | 0.74 | NR1H2 (0.50) | MAPK14KITAOC3TLR9TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2308869-B1 | AZOLE COMPOUND | ASTELLAS PHARMA INC (JP) | 2012-09-19 | — | — | EP | disclosed |
| US-8207199-B2 | Azole compound | ASTELLAS PHARMA INC. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-20110118311-A1 | AZOLE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-05-19 | — | — | US | disclosed |
| WO-2010007966-A1 | AZOLE COMPOUND | アステラス製薬株式会社 (JP) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118311-A1 | AZOLE COMPOUND | FAAH, FAAH2, TRPV1 | MKNK1 2805/4885MKNK2 2888/4885MAPK11 2180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.